Loading…
Chinese cosmetics group selling skincare brands, including acquired premium brand EviDenS de Beaute, mainly via e-commerce.
Chinese cosmetics group selling skincare brands, including acquired premium brand EviDenS de Beaute, mainly via e-commerce.
In one line: A Chinese e-commerce-led multi-brand cosmetics group.
Moat: narrow (brand, distribution). Strong livestream/e-commerce distribution capability across a multi-brand skincare portfolio.
Headquarters: Hangzhou, China · Employees: 2,082
Size SYoung (300740.SZ) is a China Consumer Staples company (Household/Personal Care) with a market value of $1.00B, the 2294th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥16.19 on 6 Nov 2026.
Performance Over six months the shares fell 36.9%, against +8.2% for the median peer and -16.4% for the China market (cap-weighted) — 2nd lowest of 21 in its peer set.
Growth Revenue grew 13.9% over the last twelve months (peer median +9.4%); the operating margin is 3.2% (peer median 9.9%).
Valuation It trades at 39.6× forward earnings against a peer median of 19.2× (3rd most expensive of 21).
Price implies For today's price to make sense, revenue must grow about 18% a year for seven years (Req g). Recent delivered growth is +6%, so the hurdle is +12 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 4.0 points below its cost of capital (10.2% WACC).
Next results Next results expected around 28 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥5.24B | CN¥4.97B | CN¥4.23B | CN¥4.48B | CN¥4.71B |
| Revenue growth | — | +17% | -6% | -5% | — |
| Gross profit | CN¥3.55B | CN¥3.18B | CN¥2.61B | CN¥2.56B | CN¥2.46B |
| EBITDA | n/a | CN¥328M | CN¥326M | CN¥460M | CN¥196M |
| Net income | CN¥113M | CN¥148M | CN¥110M | CN¥294M | CN¥125M |
| Free cash flow | CN¥480M | CN¥505M | -CN¥8.63M | CN¥86.8M | -CN¥275M |
| Capital expenditure | CN¥55.7M | CN¥69.4M | CN¥278M | CN¥178M | CN¥293M |
| Total debt | CN¥838M | CN¥1.60B | CN¥1.69B | CN¥1.45B | CN¥1.28B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| SYoung 300740.SZ | $1.00B | -37% | +14% | 3% | 39.6× | 18.1% |
| Proya Cosmetics 603605.SS | $2.97B | -19% | +2% | 13% | 11.1× | -4.8% |
| Yunnan Botanee Bio-Technology 300957.SZ | $1.84B | -28% | +7% | 9% | 21.2× | 4.5% |
| Guangdong Marubi Biotechnology 603983.SS | $1.45B | -4% | -6% | 2% | 37.0× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300740.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -26.3% | +1.6% | lowest of 21 |
| 6-month return | -36.9% | +8.2% | 2nd lowest of 21 |
| Distance from 52-week high | -42.9% | -26.4% | 3rd lowest of 21 |
| Revenue growth (TTM) | +13.9% | +9.4% | 8th highest of 21 |
| Operating margin | 3.2% | 9.9% | 3rd lowest of 21 |
| Forward P/E | 39.6× | 19.2× | 3rd most expensive of 21 |
| Growth the price implies (Req g, 7 yrs) | 18.1% | 2.9% | 3rd most demanding of 19 |
| Growth delivered (Del g) | +6.1% | +9.8% | 7th lowest of 19 |
| Hurdle (Req g minus delivered) | +12.0 pp | -6.9 pp | 2nd most demanding of 19 |
| ROIC minus cost of capital | -4.0 pp | +7.1 pp | lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| SYoung 300740.SZ | China | $1.00B | -37% | +14% | 3% | 39.6× | 18.1% | +6.1% |
| Noevir 4928.T | Japan | $977M | +3% | +1% | 16% | 19.4× | -4.8% | +4.5% |
| Tongling Jieya Biologic Technology 301108.SZ | China | $961M | +47% | +54% | 7% | 54.0× | n/a | n/a |
| Shanghai Forest Cabin Cosmetics 2657.HK | Hong Kong | $1.06B | 0% | +74% | 18% | 12.1× | 11.5% | +49.0% |
| Dencare (Chongqing) Oral Care 001328.SZ | China | $944M | +15% | +10% | 11% | 28.9× | 4.3% | +10.8% |
| Runben Biotechnology 603193.SS | China | $940M | -33% | +13% | 21% | 18.9× | 1.7% | +28.4% |
| Shanghai Chicmax Cosmetics 2145.HK | Hong Kong | $1.22B | -52% | +23% | 8% | 15.0× | -5.9% | +21.2% |
| Galaxy Surfactants GALAXYSURF.NS | India | $819M | +13% | +30% | 9% | 18.6× | 18.0% | +13.7% |
| Cosmecca Korea 241710.KS | South Korea | $798M | +25% | +44% | 13% | 14.4× | -5.9% | +13.6% |
| Edgewell Personal Care EPC | United States | $1.29B | +32% | -7% | 6% | 12.4× | 4.1% | +2.7% |
| Jyothy Labs JYOTHYLAB.NS | India | $773M | -23% | +5% | 8% | 30.9× | 35.0% | +8.9% |
| d'Alba Global 483650.KS | South Korea | $1.32B | -37% | +55% | 21% | 13.6× | -2.2% | +53.0% |
| Hangzhou Haoyue Personal Care 605009.SS | China | $750M | -19% | +10% | 6% | 17.7× | 4.7% | +7.7% |
| Guangdong Marubi Biotechnology 603983.SS | China | $1.45B | -4% | -6% | 2% | 37.0× | n/a | n/a |
| Chongqing Baiya Sanitary Products 003006.SZ | China | $1.49B | +25% | 0% | 3% | 41.2× | 30.6% | +22.8% |
| Intercos ICOS.MI | Italy | $1.50B | +16% | -5% | 9% | 19.5× | 4.5% | +11.5% |
| Milbon 4919.T | Japan | $669M | +30% | +6% | 13% | 22.9× | -3.1% | +8.2% |
| AMOREPACIFIC 002790.KS | South Korea | $1.55B | -3% | +9% | 9% | 8.4× | -17.9% | -1.3% |
| Harbin Fuerjia Technology 301371.SZ | China | $1.58B | -30% | +28% | 20% | 22.5× | 8.7% | +3.6% |
| Energizer ENR | United States | $1.63B | +26% | +2% | 16% | 7.2× | -5.2% | +1.5% |
| Pigeon 7956.T | Japan | $1.66B | +30% | +7% | 13% | 26.3× | -1.3% | +1.9% |